Article Versions Notes

Gargaun E, Falcone S, Solé G, Durigneux J, Urtizberea A, Cuisset JM, Benkhelifa-Ziyyat S, Julien L, Boland A, Sandron F, et al. The lncRNA 44s2 Study Applicability to the Design of 45-55 Exon Skipping Therapeutic Strategy for DMD. Biomedicines. 2021; 9(2):219. https://doi.org/10.3390/biomedicines9020219

Gargaun, Elena, Sestina Falcone, Guilhem Solé, Julien Durigneux, Andoni Urtizberea, Jean Marie Cuisset, Sofia Benkhelifa-Ziyyat, Laura Julien, Anne Boland, Florian Sandron, and et al. 2021. "The lncRNA 44s2 Study Applicability to the Design of 45-55 Exon Skipping Therapeutic Strategy for DMD" Biomedicines 9, no. 2: 219. https://doi.org/10.3390/biomedicines9020219

Gargaun, E., Falcone, S., Solé, G., Durigneux, J., Urtizberea, A., Cuisset, J. M., Benkhelifa-Ziyyat, S., Julien, L., Boland, A., Sandron, F., Meyer, V., Deleuze, J. F., Salgado, D., Desvignes, J.-P., Béroud, C., Chessel, A., Blesius, A., Krahn, M., Levy, N., ... Pietri-Rouxel, F. (2021). The lncRNA 44s2 Study Applicability to the Design of 45-55 Exon Skipping Therapeutic Strategy for DMD. Biomedicines, 9(2), 219. https://doi.org/10.3390/biomedicines9020219